There are other treatments in clinical development that target the FGFR3/CNP pathway for treatment of achondroplasia, including TransCon CNP (Ascendis Pharma, Copenhagen, Denmark) and infigratinib (Truseltiq; QED Therapeutics, Brisbane, CA) (25). This evidence concerns the gene FGFR3 and achondroplasia.